Akebia Therapeutics Quote - AKBA

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

1.915

Bid

1.91

Offer

1.92

Volume

1,632,282

1.86 Day's Range 1.955

0.80 52 Week Range 2.48

Market Cap

417.817M

Previous Close

1.98

Open

1.95

Last Trade

100

1.915

Last Trade Time

04:17:01

Financial Volume

US$ 3,102,973

VWAP

1.901

Average Volume (3m)

1,935,432

Shares Outstanding

218,181,202

Dividend Yield

PE Ratio

-7.90

Earnings Per Share (EPS)

-0.24

Revenue

194.62M

Net Profit

-51.93M

Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment... Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.akebia.com

Headquarters

Wilmington, Delaware, USA

Founded

Akebia Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker AKBA. The last closing price for Akebia Therapeutics was US$1.98. Over the last year, Akebia Therapeutics shares have traded in a share price range of US$ 0.80 to US$ 2.48.

Akebia Therapeutics currently has 218,181,202 shares in issue. The market capitalisation of Akebia Therapeutics is US$432 million. Akebia Therapeutics has a price to earnings ratio (PE ratio) of -7.90.

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire CAMBRIDGE, Mass., Dec. 3, 2024 CAMBRIDGE, Mass., Dec. 3, 2024 /PRNewswire/ -- Akebia Therapeutics®...

U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis

U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis PR Newswire CAMBRIDGE, Mass., Dec. 3, 2024 Outcomes study...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.145	-7.03883495146	2.06	2.0888	1.86	1623225	2.02233892	CS
4	-0.035	-1.79487179487	1.95	2.17	1.75	1971685	1.96172325	CS
12	0.545	39.7810218978	1.37	2.17	1.24	1935432	1.72869188	CS
26	0.835	77.3148148148	1.08	2.17	0.8	2154435	1.43792009	CS
52	0.805	72.5225225225	1.11	2.48	0.8	2847060	1.51765402	CS
156	-0.575	-23.0923694779	2.49	2.93	0.241	3637525	1.02969193	CS
260	-4.585	-70.5384615385	6.5	13.78	0.241	3641382	2.26099708	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
AMPGAmplitech Group Inc	US$ 2.05 (106.63%)	155.12M
LAESSEALSQ Corporation	US$ 1.155 (102.28%)	175.78M
SFIXStitch Fix Inc	US$ 6.735 (46.41%)	17.84M
CADLCandel Therapeutics Inc	US$ 6.71 (45.55%)	71.27M
PDCOPatterson Companies Inc	US$ 31.065 (34.42%)	5.51M
CLRBCellectar Biosciences Inc	US$ 0.3133 (-75.52%)	26.16M
QTTBQ32 Bio Inc	US$ 7.0662 (-71.05%)	1.38M
SFHGSamfine Creation Holdings Group Ltd	US$ 8.10 (-61.59%)	1.93M
TFFPTFF Pharmaceuticals Inc	US$ 0.168 (-44.43%)	1.78M
AQBAquaBounty Technologies Inc	US$ 0.60 (-35.39%)	301.47k
RGTIRigetti Computing Inc	US$ 6.39 (-1.54%)	218.81M
LAESSEALSQ Corporation	US$ 1.1582 (102.84%)	173.83M
AMPGAmplitech Group Inc	US$ 2.05 (106.63%)	153.7M
NVDANVIDIA Corporation	US$ 138.7682 (2.74%)	85.57M
CADLCandel Therapeutics Inc	US$ 6.6601 (44.47%)	70.36M